{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-007701","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2022-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.325301+00:00","generated_at":"2026-06-26T15:05:16.976351+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lyell Immunopharma reports Q4/FY2021 net loss $250.2M; cash $898M; two INDs cleared","bullets":["Net loss $250.2M in FY2021 vs $204.5M in 2020; non-GAAP net loss $147.9M.","R&D expense $138.7M in FY2021, down from $182.2M; G&A expense $89.1M vs $46.9M.","Cash, cash equivalents and marketable securities $898M as of Dec 31, 2021.","FDA cleared INDs for LYL797 (CAR T targeting ROR1) and LYL132 (TCR targeting NY-ESO-1); initial data from LYL797 trial expected in 2023.","LYL845 TIL therapy IND on track for H2 2022; LYL331 IND (GSK collaboration) delayed to late 2022/early 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-007701","json":"https://secwatch.observer/filing/0001628280-22-007701.json","markdown":"https://secwatch.observer/filing/0001628280-22-007701.md","text":"https://secwatch.observer/filing/0001628280-22-007701.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000162828022007701/0001628280-22-007701-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000162828022007701/lyel-20220329.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T15:05:16.976351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}